CVSS2
Attack Vector
NETWORK
Attack Complexity
LOW
Authentication
SINGLE
Confidentiality Impact
COMPLETE
Integrity Impact
COMPLETE
Availability Impact
COMPLETE
AV:N/AC:L/Au:S/C:C/I:C/A:C
CVSS3
Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
HIGH
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
EPSS
Percentile
58.9%
This advisory was originally posted to the US-CERT secure Portal library on June 23, 2015, and is being released to the NCCIC/ICS-CERT web site.
Independent researcher Billy Rios identified a vulnerability in Hospira’s Symbiq Infusion System, which can be exploited to remotely control the device, in conjunction with previously identified vulnerabilities.ICS-CERT web site: ICSA-15-161-01 Hospira Plum A+ and Symbiq Infusion Systems Vulnerabilities, https://ics-cert.us-cert.gov/advisories/ICSA-15-161-01, web site last accessed June 23, 2015. Kyle Kamke of Ramparts LLC assisted in the development of the proof-of-exploit. Hospira has verified that this vulnerability only exists in the Symbiq Infusion System. Hospira has provided compensating measures to help mitigate risks associated with this vulnerability. As previously announced by Hospira in 2013, the Symbiq Infusion System would be retired on May 31, 2015, and will be fully removed from the market by December 2015.
This vulnerability could be exploited remotely.
The following Symbiq Infusion System versions are affected:
Successful exploitation of this vulnerability, in conjunction with previously reported vulnerabilities,a could allow an attacker to remotely control the operation of the device, potentially impacting prescribed therapy and patient safety.
Impact to individual organizations depends on many factors that are unique to each organization. ICS-CERT recommends that organizations evaluate the impact of this vulnerability based on their operational environment and specific clinical usage.
Hospira is a US-based company that maintains offices in several countries around the world.
The affected product, the Symbiq Infusion System, is an intravenous pump that delivers medication to patients. The affected product is deployed across the Healthcare and Public Health Sector. The Symbiq Infusion System is used only in the US and Canada.
With remote access and elevated privileges, the Symbiq Infusion System can be remotely directed to perform unanticipated operations.
CVE-2015-3965NVD, http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2015-3965, NIST uses this advisory to create the CVE web site report. This web site will be active sometime after publication of this advisory. has been assigned to this vulnerability. A CVSS v2 base score of 7.1 has been assigned; the CVSS vector string is (AV:N/AC:M/Au:N/C:N/I:C/A:N).CVSS Calculator, http://nvd.nist.gov/cvss.cfm?version=2&vector=AV:N/AC:M/Au:N/C:N/I:C/A:N, web site last accessed June 23, 2015.
This vulnerability could be exploited remotely.
No known public exploits specifically target this vulnerability.
An attacker with medium skill would be able to exploit this vulnerability.
ICS-CERT strongly encourages asset owners to perform a risk assessment by examining their specific clinical use of the affected product in the host environment. ICS-CERT encourages asset owners to evaluate implementing the following defensive measures to protect against this and other cybersecurity risks.
For additional information about the vulnerability and compensating measures, contact Hospira’s technical support at 1-800-241-4002.
ICS-CERT reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
ICS-CERT also provides a section for recommended practices on the ICS-CERT web page at http://ics-cert.us-cert.gov/content/recommended-practices. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available in the ICS‑CERT Technical Information Paper, ICS-TIP-12-146-01B—Targeted Cyber Intrusion Detection and Mitigation Strategies, that is available for download from the ICS-CERT web site (www.ics-cert.org).
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to ICS-CERT for tracking and correlation against other incidents.
cisasurvey.gov1.qualtrics.com/jfe/form/SV_9n4TtB8uttUPaM6?product=https://www.cisa.gov/news-events/ics-advisories/icsa-15-174-01
public.govdelivery.com/accounts/USDHSCISA/subscriber/new?topic_id=USDHSCISA_138
twitter.com/CISAgov
twitter.com/intent/tweet?text=Hospira%20Symbiq%20Infusion%20System%20Vulnerability+https://www.cisa.gov/news-events/ics-advisories/icsa-15-174-01
www.dhs.gov
www.dhs.gov/foia
www.dhs.gov/performance-financial-reports
www.facebook.com/CISA
www.facebook.com/sharer/sharer.php?u=https://www.cisa.gov/news-events/ics-advisories/icsa-15-174-01&title=Hospira%20Symbiq%20Infusion%20System%20Vulnerability
www.instagram.com/cisagov
www.linkedin.com/company/cybersecurity-and-infrastructure-security-agency
www.linkedin.com/sharing/share-offsite/?url=https://www.cisa.gov/news-events/ics-advisories/icsa-15-174-01
www.oig.dhs.gov/
www.usa.gov/
www.whitehouse.gov/
www.youtube.com/@cisagov
mailto:?subject=Hospira%20Symbiq%20Infusion%20System%20Vulnerability&body=www.cisa.gov/news-events/ics-advisories/icsa-15-174-01
CVSS2
Attack Vector
NETWORK
Attack Complexity
LOW
Authentication
SINGLE
Confidentiality Impact
COMPLETE
Integrity Impact
COMPLETE
Availability Impact
COMPLETE
AV:N/AC:L/Au:S/C:C/I:C/A:C
CVSS3
Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
HIGH
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
EPSS
Percentile
58.9%